FDA clears Pfizer's Xeljanz for inflammatory bowel disease

Reuters Health Information: FDA clears Pfizer's Xeljanz for inflammatory bowel disease

FDA clears Pfizer's Xeljanz for inflammatory bowel disease

Last Updated: 2018-05-30

By Reuters Staff

(Reuters) - The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent of the patients.

The FDA's announcement is here: http://bit.ly/2kA4FJN.

The drug is already approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.